Il-1 family variants

Abstract

The present invention provides compositions and methods relating to IL-1Rrp2 requiring proteins.

What is claimed is: 
     
         1 . A method of treating an inflammatory or autoimmune condition in a subject wherein the inflammatory or autoimmune condition is mediated by IL-1Rrp2, comprising administering to the subject an IL-1F5 polypeptide that antagonizes signal transduction through IL-1Rrp2, comprising the amino acid sequence set forth in SEQ ID NO: 8, wherein the N-terminus of said IL-1F5 polypeptide starts at amino acid position one of the amino acid sequence set forth in SEQ ID NO: 8, wherein the amount of the IL-1F5 polypeptide is sufficient to reduce at least one symptom of the inflammatory or autoimmune condition in the subject. 
     
     
         2 . The method of  claim 1 , wherein the condition to be treated is an inflammatory condition of the skin, lungs or airways mediated by IL-1Rrp2. 
     
     
         3 . The method of  claim 1 , wherein the condition to be treated is selected from the group consisting of psoriasis, seborrheic dermatitis, atopic dermatitis, including chronic atopic dermatitis, allergic contact dermatitis, lichen simplex chronicus, pityriasis rubra pilaris, nummular dermatitis, asthma, allergic rhinitis, gastro-esophageal reflux disease, arthritic conditions including, rheumatoid arthritis, psoriatic arthritis, and osteoarthritis. 
     
     
         4 . The method of  claim 1 , wherein the subject is human. 
     
     
         5 . The method of  claim 2 , wherein the subject is human. 
     
     
         6 . The method of  claim 3 , wherein the subject is human.